AAO: Alimera highlights NEW DAY Study for sustained-release intravitreal implant

Video
Conference|AAO

Rick Eiswirth, president and CEO of Alimera Sciences, provides an update on the company’s clinical trial that aims to evaluate its fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien) as a baseline therapy for diabetic macular edema.


Rick Eiswirth, president and CEO of Alimera Sciences, provides an update on the company’s clinical trial that aims to evaluate its fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien) as a baseline therapy for diabetic macular edema.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Recent Videos
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Related Content
European Union flags outside the Berlaymont building in Brussels, Belgium, the headquarters of the European Commission. Concept image for ZEISS Medical Technology CE Mark CIRRUS PathFinder AI. Image credit: © olrat – stock.adobe.com

European Commission issues CE mark for Zeiss CIRRUS PathFinder AI tool

Hattie Hayes
August 22nd 2025
Article
PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

August 22nd 2025
Podcast
A surgical tray sits on a dirt road. There are visible scalpels and other metal tools. Concept image for ocular trauma, conflict and combat zones, eye surgery and emergency ophthalmology in low-resource, high-conflict regions or war zones. Created by Jennifer Toomey using Adobe Firefly AI.

Clinicians keep their eyes on wartime ocular trauma

Oksana Vitovska, MD; Sibylle Scholtz, PhD;Hattie Hayes
August 22nd 2025
Article
PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

August 22nd 2025
Podcast
Tyson J. Brunstetter, MBA, OD, PhD, FAAO, FAsMA presents a keynote on spaceflight-associated neuro-ocular syndrome (SANS). (All images courtesy of Heidelberg Engineering)

Recap: The future of imaging is out of this world

Hattie Hayes
August 22nd 2025
Article
A glass building with a sign reading "RESERVE BANK." There are $100 Australian bank notes superimposed over the image. Concept image for Mirugen funding, cell reprogramming biologic biotech business of retina care news. Image credit: ©Rose Makin – stock.adobe.com

Australian biotech firm Mirugen secures major funding for cell reprogramming therapy

Hattie Hayes
August 22nd 2025
Article
© 2025 MJH Life Sciences

All rights reserved.